Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
Clinical trial NCT03519971 · COMPLETED
Trial details
- NCT number
- NCT03519971
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2018-03-29
- Primary completion
- 2023-09-07
- Enrollment
- 328
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.